REDWOOD CITY, Calif. — October 10, 2025 — Leads & Copy — Seer, Inc. (Nasdaq: SEER) will participate in the American Society of Human Genetics (ASHG) 2025 Annual Meeting from October 14-18 in Boston. Seer will host a CoLab session and be represented in scientific presentations, demonstrating how the Proteograph® Product Suite translates genomic data into biological and clinical insight.
The CoLab session, titled “Advancing Precision Medicine Through Multi-Omics: Clinical Insights from Xenotransplantation and Fibrosis,” will highlight how multi-omic approaches powered by Seer’s Proteograph Product Suite are transforming translational genomics and clinical research. Brendan Keating, PhD, NYU Langone Health, will present findings from gene-edited pig organ xenotransplants into humans. Gloria Sheynkman, PhD, University of Virginia School of Medicine, will discuss how proteomic profiling identified isoform-specific biomarkers predicting survival differences in idiopathic pulmonary fibrosis.
Several independent research groups will present findings using Seer’s Proteograph platform, exploring how Seer’s proteomic data can clarify prior findings and integrate with genomic datasets for disease discovery. Presentations include “Triangulating orthogonal proteomic profiling methods to yield high-confidence protein targets” by Joshua Bis and “Proteogenomic prioritization of human knock-out mutations provides novel insights into function and clinical impact of genes across the genome and clinical specialties” by Claudia Langenberg.
Omid Farokhzad, Chair and CEO of Seer, noted the rising importance of proteomics among genomics researchers and stated that Seer’s platform helps researchers connect genetic variation to biological function through deep, unbiased proteomics at scale.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility. Seer’s products are for research use only and are not intended for diagnostic procedures.
Patrick Schmidt
pr@seer.bio
Carrie Mendivil
investor@seer.bio
Source: Seer, Inc.
